Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase

被引:65
|
作者
Hamstra, DA
Rice, DJ
Fahmy, S
Ross, BD
Rehemtulla, A
机构
[1] Univ Michigan, Sch Med, Dept Radiat Oncol, Med Ctr, Ann Arbor, MI 48105 USA
[2] Univ Michigan, Med Ctr, Dept Pharmacol, Ann Arbor, MI 48105 USA
[3] Univ Michigan, Med Ctr, Dept Radiol, Ann Arbor, MI 48105 USA
[4] Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48105 USA
关键词
D O I
10.1089/10430349950017356
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The use of cytosine deaminase (CD) in conjunction with 5-fluorocytosine (5-FC) has been studied for cancer gene therapy as a means of achieving tumor-specific generation of the toxic metabolite 5-fluorouracil (5-FU), Since 5-FC is frequently used as an antifungal agent, and because it has little or no efficacy as an antibacterial agent, we hypothesized that yeast CD (YCD) might be more efficient at utilizing 5-FC as a substrate and hence be a better choice for a CD/5-FC gene therapy strategy than the typically utilized bacterial CD (BCD), To that end Saccharomyces cerevisiae CD was cloned from yeast genomic DNA and expressed in vitro. Functional analysis of BCD and YCD expressed in COS-1 cells indicated that BCD and YCD both utilized cytosine with equal efficacy; however, 5-FC was an extremely poor substrate for BCD, with an apparent catalytic efficiency 280-fold lower than that observed for YCD, Retroviral infection of tumor cell lines in vitro indicated that the IC50 of 5-FC was 30-fold lower in PCD-infected cultures as compared with cultures infected with BCD retrovirus, In addition, when SCCVII murine squamous cell carcinoma cells were infected in vitro at low rates of infection (less than or equal to 10%) there was no significant cytotoxicity toward BCD-expressing cells while there was potent cytotoxicity to both YCD-expressing cells and "bystander cells" even at this low level of expression. Finally, stable BCD- or YCD-expressing SCCVII clones were developed and used in an orthotopic immune-competent model of head and neck cancer. Subsequent treatment with 5-FC followed by monitoring of tumor growth by noninvasive magnetic resonance imaging (MRI) and survival of animals indicated a growth delay during the course of 5-FC treatment for BCD-expressing tumors, which quickly regrew at the end of treatment. In contrast, YCD-expressing tumors exhibited not only a growth delay, which was of longer duration, but also in some cases frank tumor regression and complete cures occurred.
引用
收藏
页码:1993 / 2003
页数:11
相关论文
共 50 条
  • [31] Strategies for enzyme/prodrug cancer therapy
    Xu, G
    McLeod, HL
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3314 - 3324
  • [32] p53-selectively replicating adenoviruses expressing the cytosine deaminase prodrug converting enzyme.
    Laquerre, S
    Young, MD
    Johnson, L
    Nye, J
    Hawkins, L
    Weber, S
    Holman, P
    Lemmon, M
    McCoy, S
    Cohen, L
    Collard, W
    Hermiston, T
    CLINICAL CANCER RESEARCH, 2000, 6 : 4570S - 4570S
  • [33] ENZYME/PRODRUG GENE-THERAPY - COMPARISON OF CYTOSINE DEAMINASE/5-FLUOROCYTOSINE VERSUS THYMIDINE KINASE/GANCICLOVIR ENZYME/PRODRUG SYSTEMS IN A HUMAN COLORECTAL-CARCINOMA CELL-LINE
    TRINH, QT
    AUSTIN, EA
    MURRAY, DM
    KNICK, VC
    HUBER, BE
    CANCER RESEARCH, 1995, 55 (21) : 4808 - 4812
  • [34] Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyttransferase suicide system
    Miyagi, T
    Koshida, K
    Hori, O
    Konaka, H
    Katoh, H
    Kitagawa, Y
    Mizokami, A
    Egawa, M
    Ogawa, S
    Hamada, H
    Namiki, M
    JOURNAL OF GENE MEDICINE, 2003, 5 (01): : 30 - 37
  • [35] Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy
    Arunas Kazlauskas
    Adas Darinskas
    Rolandas Meškys
    Arimantas Tamašauskas
    Jaunius Urbonavičius
    BMC Cancer, 19
  • [36] Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy
    Kazlauskas, Arunas
    Darinskas, Adas
    Meskys, Rolandas
    Tamasauskas, Arimantas
    Urbonavicius, Jaunius
    BMC CANCER, 2019, 19 (1)
  • [37] Exogeneous cytosine deaminase gene expression in Bifidobacterium breve 1-53-8w for tumor-targeting enzyme/prodrug therapy
    Hidaka, Ayurni
    Hamaji, Yoshinori
    Sasaki, Takayuki
    Taniguchi, Shun'ichiro
    Fujimori, Minoru
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2007, 71 (12) : 2921 - 2926
  • [38] Gene directed enzyme prodrug therapy for cancer
    McNeish, IA
    Searle, PF
    Young, LS
    Kerr, DJ
    ADVANCED DRUG DELIVERY REVIEWS, 1997, 26 (2-3) : 173 - 184
  • [39] Enzyme/Prodrug Systems for Cancer Gene Therapy
    Malekshah O.M.
    Chen X.
    Nomani A.
    Sarkar S.
    Hatefi A.
    Current Pharmacology Reports, 2016, 2 (6) : 299 - 308
  • [40] Enzyme/prodrug gene therapy for human colon cancer cells using adenovirus-mediated transfer of the Escherichia coli cytosine deaminase gene driven by a CAG promoter associated with 5-fluorocytosine administration
    Koyama, F
    Sawada, H
    Fujii, H
    Hirao, T
    Ueno, M
    Hamada, H
    Nakano, H
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2000, 19 (01) : 75 - 80